HIMS
Hims & Hers Health, Inc.
Medical - Equipment & Services
Market Cap$6.94B
5Y Perf.+170.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HIMS vs LLY
Revenue, margins, valuation, and 5-year total return — side by side.
LLY
Eli Lilly and Company
Drug Manufacturers - General
Market Cap$932.64B
5Y Perf.+545.4%
HIMS vs LLY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HIMS | LLY |
|---|---|---|
| Industry | Medical - Equipment & Services | Drug Manufacturers - General |
| Market Cap | $6.94B | $932.64B |
| Revenue (TTM) | $2.35B | $72.25B |
| Net Income (TTM) | $128M | $25.27B |
| Gross Margin | 69.7% | 83.5% |
| Operating Margin | 4.6% | 45.9% |
| Forward P/E | 53.9x | 28.6x |
| Total Debt | $1.12B | $42.50B |
| Cash & Equiv. | $229M | $7.16B |
HIMS vs LLY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HIMS
LLY
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Hims & Hers Health,… (HIMS) | 100 | 270.6 | +170.6% |
| Eli Lilly and Compa… (LLY) | 100 | 645.4 | +545.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HIMS vs LLY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LLY leads in 6 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Hims & Hers Health, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
HIMS
Hims & Hers Health, Inc.
The Growth Play
HIMS is the clearest fit if your priority is growth exposure.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 59.0% revenue growth vs LLY's 44.7%
Best for: growth exposure
LLY
Eli Lilly and Company
The Income Pick
LLY carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 11 yrs, beta 0.71, yield 0.6%
- 12.7% 10Y total return vs HIMS's 174.3%
- Lower volatility, beta 0.71, current ratio 1.58x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HIMS | 59.0% revenue growth vs LLY's 44.7% |
| Value | LLY | Lower P/E (28.6x vs 53.9x) |
| Quality / Margins | LLY | 35.0% margin vs HIMS's 5.5% |
| Stability / Safety | LLY | Beta 0.71 vs HIMS's 2.40, lower leverage |
| Dividends | LLY | 0.6% yield; 11-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | LLY | +28.2% vs HIMS's -45.7% |
| Efficiency (ROA) | LLY | 22.7% ROA vs HIMS's 6.0%, ROIC 41.8% vs 10.7% |
HIMS vs LLY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
HIMS vs LLY — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLLYLAGGINGHIMS
HIMSHims & Hers Health, I…
0leads
LLYEli Lilly and Company
4leads
6 Total Categories
CATEGORYLEADERvs HIMSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LLY6/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LLY6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
LLY6/6
Risk & VolatilityBeta, volatility, and downside exposure
LLY2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LLY leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LLY is the larger business by revenue, generating $72.2B annually — 30.8x HIMS's $2.3B. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to HIMS's 5.5%. On growth, LLY holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | HIMSHims & Hers Healt… | LLYEli Lilly and Com… |
|---|---|---|
| RevenueTrailing 12 months | $2.3B | $72.2B |
| EBITDAEarnings before interest/tax | $164M | $34.7B |
| Net IncomeAfter-tax profit | $128M | $25.3B |
| Free Cash FlowCash after capex | $73M | $13.6B |
| Gross MarginGross profit ÷ Revenue | +69.7% | +83.5% |
| Operating MarginEBIT ÷ Revenue | +4.6% | +45.9% |
| Net MarginNet income ÷ Revenue | +5.5% | +35.0% |
| FCF MarginFCF ÷ Revenue | +3.1% | +18.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +28.4% | +55.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -27.3% | +169.9% |
LLY leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
Evenly matched — HIMS and LLY each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 43.0x trailing earnings, LLY trades at a 18% valuation discount to HIMS's 52.7x P/E. On an enterprise value basis, LLY's 31.0x EV/EBITDA is more attractive than HIMS's 44.5x.
| Metric | HIMSHims & Hers Healt… | LLYEli Lilly and Com… |
|---|---|---|
| Market CapShares × price | $6.9B | $932.6B |
| Enterprise ValueMkt cap + debt − cash | $7.8B | $968.0B |
| Trailing P/EPrice ÷ TTM EPS | 52.71x | 43.01x |
| Forward P/EPrice ÷ next-FY EPS est. | 53.94x | 28.59x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.49x |
| EV / EBITDAEnterprise value multiple | 44.46x | 30.97x |
| Price / SalesMarket cap ÷ Revenue | 2.96x | 14.31x |
| Price / BookPrice ÷ Book value/share | 12.83x | 33.41x |
| Price / FCFMarket cap ÷ FCF | 93.85x | 103.95x |
Evenly matched — HIMS and LLY each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
LLY leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $24 for HIMS. LLY carries lower financial leverage with a 1.60x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs HIMS's 4/9, reflecting strong financial health.
| Metric | HIMSHims & Hers Healt… | LLYEli Lilly and Com… |
|---|---|---|
| ROE (TTM)Return on equity | +23.7% | +101.2% |
| ROA (TTM)Return on assets | +6.0% | +22.7% |
| ROICReturn on invested capital | +10.7% | +41.8% |
| ROCEReturn on capital employed | +10.9% | +46.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 8 |
| Debt / EquityFinancial leverage | 2.07x | 1.60x |
| Net DebtTotal debt minus cash | $892M | $35.3B |
| Cash & Equiv.Liquid assets | $229M | $7.2B |
| Total DebtShort + long-term debt | $1.1B | $42.5B |
| Interest CoverageEBIT ÷ Interest expense | — | 35.68x |
LLY leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
LLY leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LLY five years ago would be worth $52,144 today (with dividends reinvested), compared to $25,051 for HIMS. Over the past 12 months, LLY leads with a +28.2% total return vs HIMS's -45.7%. The 3-year compound annual growth rate (CAGR) favors LLY at 32.4% vs HIMS's 31.4% — a key indicator of consistent wealth creation.
| Metric | HIMSHims & Hers Healt… | LLYEli Lilly and Com… |
|---|---|---|
| YTD ReturnYear-to-date | -19.5% | -8.5% |
| 1-Year ReturnPast 12 months | -45.7% | +28.2% |
| 3-Year ReturnCumulative with dividends | +126.8% | +131.9% |
| 5-Year ReturnCumulative with dividends | +150.5% | +421.4% |
| 10-Year ReturnCumulative with dividends | +174.3% | +1271.7% |
| CAGR (3Y)Annualised 3-year return | +31.4% | +32.4% |
LLY leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
LLY leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LLY is the less volatile stock with a 0.71 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 87.1% from its 52-week high vs HIMS's 38.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HIMSHims & Hers Healt… | LLYEli Lilly and Com… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.40x | 0.71x |
| 52-Week HighHighest price in past year | $70.43 | $1133.95 |
| 52-Week LowLowest price in past year | $13.74 | $623.78 |
| % of 52W HighCurrent price vs 52-week peak | +38.2% | +87.1% |
| RSI (14)Momentum oscillator 0–100 | 52.8 | 61.6 |
| Avg Volume (50D)Average daily shares traded | 35.4M | 2.6M |
LLY leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HIMS as "Hold" and LLY as "Buy". Consensus price targets imply 27.5% upside for LLY (target: $1258) vs 10.4% for HIMS (target: $30). LLY is the only dividend payer here at 0.61% yield — a key consideration for income-focused portfolios.
| Metric | HIMSHims & Hers Healt… | LLYEli Lilly and Com… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $29.67 | $1258.47 |
| # AnalystsCovering analysts | 19 | 45 |
| Dividend YieldAnnual dividend ÷ price | — | +0.6% |
| Dividend StreakConsecutive years of raises | — | 11 |
| Dividend / ShareAnnual DPS | — | $6.00 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.3% | +0.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
LLY leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallEli Lilly and Company (LLY)Leads 4 of 6 categories
Loading custom metrics...
HIMS vs LLY: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is HIMS or LLY a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 44. 7% for Eli Lilly and Company (LLY). Eli Lilly and Company (LLY) offers the better valuation at 43. 0x trailing P/E (28. 6x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HIMS or LLY?
On trailing P/E, Eli Lilly and Company (LLY) is the cheapest at 43.
0x versus Hims & Hers Health, Inc. at 52. 7x. On forward P/E, Eli Lilly and Company is actually cheaper at 28. 6x.
03Which is the better long-term investment — HIMS or LLY?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +421.
4%, compared to +150. 5% for Hims & Hers Health, Inc. (HIMS). Over 10 years, the gap is even starker: LLY returned +1272% versus HIMS's +174. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HIMS or LLY?
By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.
71β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 239% more volatile than LLY relative to the S&P 500. On balance sheet safety, Eli Lilly and Company (LLY) carries a lower debt/equity ratio of 160% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — HIMS or LLY?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus 44. 7% for Eli Lilly and Company (LLY). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HIMS or LLY?
Eli Lilly and Company (LLY) is the more profitable company, earning 31.
7% net margin versus 5. 5% for Hims & Hers Health, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 5. 2% for HIMS. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HIMS or LLY more undervalued right now?
On forward earnings alone, Eli Lilly and Company (LLY) trades at 28.
6x forward P/E versus 53. 9x for Hims & Hers Health, Inc. — 25. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LLY: 27. 5% to $1258. 47.
08Which pays a better dividend — HIMS or LLY?
In this comparison, LLY (0.
6% yield) pays a dividend. HIMS does not pay a meaningful dividend and should not be held primarily for income.
09Is HIMS or LLY better for a retirement portfolio?
For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
71), 0. 6% yield, +1272% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1272%, HIMS: +174. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HIMS and LLY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
LLY pays a dividend while HIMS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(HIMS: 28.4% · LLY: 55.5%)Net Margin>
%
(HIMS: 5.5% · LLY: 35.0%)P/E Ratio<
x
(HIMS: 52.7x · LLY: 43.0x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.